China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
SC
SCMP - Feed 91By Xinmei Shen
EXECUTIVE SUMMARY
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...
Key Takeaways
- Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug.
- GLP-1 receptor agonists are synthetic...
- GLP-1 receptor agonists are synthetic...
Read Complete Original Article
Published originally on SCMP - Feed 91
